This study aimed to explore the influence of SLC22A1, PXR, ABCG2, ABCB1 and CYP3A5*3 genetic polymorphisms on imatinib mesylate (IM) pharmacokinetics in Asian patients with chronic myeloid leukemia (CML). The gene discussed is CYP3A5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.